Non-Small-Cell Lung Carcinoma, Pancreatic Cancer, Renal Cell Carcinoma
Conditions
Brief summary
The drug ABR-217620 is a combination of two proteins, one that recognizes tumor cells and one that triggers an attack on the tumor cells by activating some white blood cells belonging to the body's normal immune system. In animals, this results in an accumulation of white blood cells in the cancer that can fight the cancer. This study will test how much of the drug can be given to patients with non-small cell lung cancer, renal clear cell carcinoma, or pancreatic cancer without causing unacceptable side effects.
Interventions
DRUGABR-217620
Starting dose: 0.5 mcg/kg; subsequent doses: individual, based on pre-treatment level of anti-SEA/E-120, body weight, and toxicities observed in prior patients on study; IV; one bolus injection each day for 5 consecutive days; up to 3 cycles
Sponsors
Active Biotech AB
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with histologically or cytologically confirmed non-small cell lung cancer, which is refractory to (progressed on or following) currently available standard therapies. Patients must have received (or declined) at least one standard regimen for advanced/metastatic disease. * ECOG performance status of 0 or 1. * Adequate bone marrow function as defined by absolute neutrophil count greater than or equal to 1500/mm3, and platelets greater than or equal to 100,000/mm3, and hemoglobin greater than or equal to 10 g/dL. * Adequate renal function: creatinine less than or equal to 1.5 x upper limit of normal. * Adequate hepatic function: bilirubin less than or equal to 2 x upper limit of normal, and SGOT (S-ASAT) and SGPT (S-ALAT) less than or equal to 2.5 x upper limit of normal. * Life expectancy greater than 3 months.
Exclusion criteria
* Pregnant or breast-feeding women, or women of childbearing potential unless effective methods of contraception are used. * A serious uncontrolled medical disorder or active infection that would impair the patient's ability to receive study treatment. * History of or any concurrent malignancy, with the exception of the following malignancies, which may still be included: non-melanoma skin cancer, cervical cancer in situ, DCIS or LCIS of breast, past history of resected melanoma without clinical evidence of recurrent melanoma, past history of prostate cancer without clinical evidence of disease (includes patients receiving hormonal therapy). * History of brain metastases, unless stable for more than 4 weeks, and not requiring steroid therapy and without clinical symptoms of brain metastases. * Acute illness or evidence of infection, including unexplained fever (temperature greater than 100.5 degrees Fahrenheit or 38.1 degrees Celsius). * Significant symptomatic cardiac disease including: history (within the past 6 months) or current unstable angina, congestive heart failure, or myocardial infarction; or patients with uncontrolled hypertension, or hypertension that is controlled only with multiply drugs (control by monotherapy is permitted). * History of or current arrhythmias requiring treatment, with the exception of non-specific, asymptomatic ST-T wave changes or extrasystoles. * History of cerebrovascular accident within the past 5 years. * Seizure disorder requiring therapy. * Treatment with beta-blockers, including topical therapy for glaucoma, during the 6-day treatment period (5 days' treatment + 1 day in patient follow-up), and within five days prior to start of treatment. * Simultaneous participation in any other study involving investigational drugs or having participated in a study less than 4 weeks prior to start of study treatment. * Treatment with systemic or inhaled corticosteroids within 2 weeks prior to the start of treatment. * Treatment with anticoagulants, except when used to maintain the patency of a central venous line. * Active autoimmune disease requiring therapy or any history of systemic lupus erythematosus or rheumatoid arthritis. * Chemo/radio/immunotherapy less than 4 weeks (6 weeks for mitomycin C and nitrosoureas) before start of treatment. * Major surgery less than 3 weeks. * Known positive serology for HIV (patients with a known history of HIV will be excluded because of potential for unforeseen toxicity and morbidity in the immunocompromised host). * Known chronic Hepatitis B or C. * Previous exposure to murine monoclonal antibody (with HAMA titer above detection limit at baseline) or known hypersensitivity to murine proteins. * Patients currently on renal dialysis treatment. * Known allergy or hypersensitivity to aminoglycosides e.g. kanamycin.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Maximum Tolerated Dose (MTD) as a function of pre-treatment anti-SEA/E-120 levels | 56 days after start of first treatment cycle |
Secondary
| Measure | Time frame |
|---|---|
| Safety profile | During or after first treatment cycle, second treatment cycle, later cycles if available |
| Pharmacokinetic parameters | Days 1 and 5 of each cycle |
| Immunological response | Days 28 and 56 of first and second treatment cycles, later cycles if available |
| Objective response rate | Days 28 and 56 of first and second treatment cycles, later cycles if available |
| Time to progression and Survival | Followed for up to 2 years |
Countries
Norway, United Kingdom, United States
Outcome results
None listed